[go: up one dir, main page]

NO20084291L - 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister - Google Patents

2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister

Info

Publication number
NO20084291L
NO20084291L NO20084291A NO20084291A NO20084291L NO 20084291 L NO20084291 L NO 20084291L NO 20084291 A NO20084291 A NO 20084291A NO 20084291 A NO20084291 A NO 20084291A NO 20084291 L NO20084291 L NO 20084291L
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
accompanied
urticaria
itching
solvate
Prior art date
Application number
NO20084291A
Other languages
English (en)
Inventor
Timothy Alan Gillespy
Keith John Harris
David Stefany
Joacy C Aguiar
Charles J Gardner
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20084291L publication Critical patent/NO20084291L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)

Abstract

Foreliggende oppfinnelse angår en forbindelse med formel (I) hvori Rog Rer som definert heri, eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav, et farmasøytisk akseptabelt prodmg derav eller et farmasøytisk akseptabelt salt, hydrat eller solvat av prodmget, en farmasøytisk sammensetning som innbefatter en farmasøytisk effektiv mengde av en eller flere forbindelser ifølge oppfinnelsen blandet med en farmasøytisk akseptabel bærer, en fremgangsmåte for behandling av en pasient som lider av en PGD2 forstyrrelse som inkluderer, men er ikke begrenset til, allergisk sykdom (slik som allergisk rinitt, allergisk konjunktivitt, topisk dermatitt, bronkial astma og matallergi), systemisk mastocytose, forstyrrelser ledsaget av systemisk mastcelleaktivering, anafylaksisjokk, bronkokonstriksjon, bronkitt, urtikari, eksem, sykdommer ledsaget av kløe (slik som atopisk dermatitt og urtikari), sykdommer (slike som katarakt, retinal løsning, inflammasjon, infeksjon og søvnforstyrrelser) som genereres sekundært som et resultat av atferd ledsaget av kløen, (slik som skraping og banking), inflammasjon, kronisk obstruktiv lungesykdom, iskemisk reperfunksjonsskade, cerebrovaskulær ulykke, kronisk reumatoid artritt, pleurisy, ulcerativ kolitt og lignende ved administrering til nevnte pasient en farmasøytisk effektiv mengde av en forbindelse ifølge oppfinnelsen.
NO20084291A 2006-04-12 2008-10-14 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister NO20084291L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74467606P 2006-04-12 2006-04-12
PCT/US2007/066481 WO2007121280A1 (en) 2006-04-12 2007-04-12 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists

Publications (1)

Publication Number Publication Date
NO20084291L true NO20084291L (no) 2008-11-11

Family

ID=38294040

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084291A NO20084291L (no) 2006-04-12 2008-10-14 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister

Country Status (25)

Country Link
US (1) US20090036469A1 (no)
EP (1) EP2010503A1 (no)
JP (1) JP2009533473A (no)
KR (1) KR20080108287A (no)
CN (1) CN101421252B (no)
AR (1) AR060403A1 (no)
AU (1) AU2007238052B2 (no)
BR (1) BRPI0710710A2 (no)
CA (1) CA2649083C (no)
CR (1) CR10249A (no)
DO (1) DOP2007000068A (no)
EC (1) ECSP088813A (no)
HN (1) HN2008001530A (no)
MA (1) MA30409B1 (no)
MX (1) MX2008011369A (no)
NO (1) NO20084291L (no)
NZ (1) NZ571793A (no)
PE (1) PE20080186A1 (no)
RU (1) RU2431631C2 (no)
TN (1) TNSN08339A1 (no)
TW (1) TW200815395A (no)
UA (1) UA95950C2 (no)
UY (1) UY30283A1 (no)
WO (1) WO2007121280A1 (no)
ZA (1) ZA200807380B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5039594B2 (ja) * 2008-02-08 2012-10-03 株式会社日立ハイテクノロジーズ レビュー装置，検査領域設定支援システム、および、欠陥の画像得方法
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
TW201204708A (en) * 2010-03-16 2012-02-01 Aventis Pharma Inc A substituted pyrimidine as a prostaglandin D2 receptor antagonist
EP2547672A1 (en) * 2010-03-16 2013-01-23 Aventis Pharmaceuticals Inc. Substituted pyrimidines as prostaglandin d2 receptor antagonists
EP2590944B1 (en) 2010-07-05 2015-09-30 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
US8785467B2 (en) * 2010-09-30 2014-07-22 Merck Sharp & Dohme Corp. Alkoxy pyrimidine PDE10 inhibitors
US9255090B2 (en) 2011-12-21 2016-02-09 Actelion Pharmaceuticals Ltd. Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
RU2673084C2 (ru) * 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
US20220408745A1 (en) * 2019-09-13 2022-12-29 Meiji Co., Ltd. Solid food and solid milk having hole penetrating first face and second face
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
EP4076661A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3644799A1 (de) * 1986-06-04 1987-12-10 Hoechst Ag Neue pyrimidin-derivate, deren herstellung und verwendung
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2

Also Published As

Publication number Publication date
PE20080186A1 (es) 2008-04-15
MA30409B1 (fr) 2009-05-04
AU2007238052A1 (en) 2007-10-25
CA2649083A1 (en) 2007-10-25
UY30283A1 (es) 2007-11-30
US20090036469A1 (en) 2009-02-05
AU2007238052B2 (en) 2011-12-22
JP2009533473A (ja) 2009-09-17
HK1131975A1 (en) 2010-02-12
RU2008144578A (ru) 2010-05-20
HN2008001530A (es) 2012-01-17
DOP2007000068A (es) 2007-10-31
ZA200807380B (en) 2009-05-27
BRPI0710710A2 (pt) 2011-08-16
AR060403A1 (es) 2008-06-11
KR20080108287A (ko) 2008-12-12
WO2007121280A1 (en) 2007-10-25
ECSP088813A (es) 2008-11-27
CR10249A (es) 2008-11-26
MX2008011369A (es) 2008-09-18
TW200815395A (en) 2008-04-01
TNSN08339A1 (en) 2009-12-29
RU2431631C2 (ru) 2011-10-20
CN101421252B (zh) 2011-10-12
EP2010503A1 (en) 2009-01-07
CA2649083C (en) 2011-06-28
CN101421252A (zh) 2009-04-29
NZ571793A (en) 2011-08-26
UA95950C2 (en) 2011-09-26

Similar Documents

Publication Publication Date Title
NO20084291L (no) 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister
NO20072440L (no) 2,6-substituert-4-monosubstituertamino-pyrimidin som prostaglanding D2 reseptor antagonister
NO20082072L (no) Dihydrogen fosfatsalt av en prostaglandin D2 reseptorantagonist
TNSN07251A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
NO20090862L (no) 2-fenyl-indoler som prostaglandin D2-reseptorantagonister
NO20024281L (no) Indolderivater, fremgangsmÕte for fremstilling av de samme og anvendelse derav
BRPI0511344A (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto combinado
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
KR20120006033A (ko) Ｐ38 ｍａｐ 키나제 억제제
WO2009126530A3 (en) Piperidine derivatives as cgrp receptor antagonists
NO20090139L (no) Substituted phenyl acetic acids as DP-2 antagonists
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
NO20070076L (no) Nye indazolkarboksamider og deres anvendelse
NO20073436L (no) Nye heterosykliske forbindelser nyttige for behandling av inflammatoriske og allergiske forstyrrelser
NO20061207L (no) Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel
WO2006085212A3 (en) Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
TW200635932A (en) New pyridothienopyrimidine derivatives
UA95303C2 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
TH79783A (th) ไพริมิดีนเป็นสารต้านตัวรับพรอสตาแกลนดิน ดี2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application